<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00371904</url>
  </required_header>
  <id_info>
    <org_study_id>RAPTURE</org_study_id>
    <nct_id>NCT00371904</nct_id>
  </id_info>
  <brief_title>Trial of Rituximab Given Pre-Transplant to Sensitised Live Donor Kidney Recipients</brief_title>
  <acronym>RAPTURE</acronym>
  <official_title>A Prospective Open Label Randomised Multicentre Study Evaluating the Efficacy &amp; Safety of Rituximab Given Pre-Transplant to Sensitised Renal Allograft Recipients in Addition to a &quot;Standard&quot; Desensitisation Regimen Consisting of PE/IVIG &amp; MMF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunter and New England Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Alexandra Hospital, Brisbane, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Prince Alfred Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Auckland City Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash Medical Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Perth Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Westmead Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Adelaide Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunter and New England Health</source>
  <brief_summary>
    <textblock>
      About one third of prospective kidney transplant recipients have antibodies in their blood
      directed against the tissues of their only available kidney donor. Recently,
      &quot;desensitisation&quot; treatments when administered pre-transplant have allowed successful
      transplantation of these patients despite high rates of acute antibody mediated rejection
      (AAMR). The investigators propose to test in a randomised controlled trial whether rituximab,
      a monoclonal antibody that depletes B-lymphocytes, will safely lower antibody mediated
      rejection (AMR) rates when added to &quot;standard&quot; therapy. The investigators will also test
      whether rituximab enables more patients to achieve a negative crossmatch against their donor
      and thereby allow more transplants to proceed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to investigate in a prospective, randomised fashion whether a single
      intravenous dose of rituximab (375 mg/m2) given two weeks prior to transplant, in addition to
      standard therapy, will allow sensitised renal transplant subjects to achieve a negative CDC
      crossmatch and thereby proceed to live donor transplantation. We will also evaluate whether
      rituximab will reduce the number of AAMR episodes in the post-transplant period, compared to
      controls. All eligible subjects must have a positive T- and/or B-cell CDC or flow cytometry
      crossmatch and have donor-specific antibodies identified by solid-phase assay at screening.
      All subjects will receive a standard desensitisation regimen that includes plasma
      exchange/IVIG + MMF before and immediately after transplantation followed by a standard care
      immunosuppressive regimen (IL-2R antagonist, tacrolimus, mycophenolate mofetil [MMF] and
      corticosteroids) after transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy proven antibody mediated rejection</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination of donor specific antibodies (DSA)</measure>
    <time_frame>Day - 2 , 7; Months 1, 3, 6, 9 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C4d in biopsies</measure>
    <time_frame>Day 7; Months 3 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma exchanges</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treated rejection</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss</measure>
    <time_frame>Months 3, 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure</measure>
    <time_frame>Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculation of glomerular filtration rate (GFR)</measure>
    <time_frame>Months 1 - 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of 1/serum creatinine (Ser. Cr)</measure>
    <time_frame>Months 6 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-hour U protein</measure>
    <time_frame>Months 3 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer and infections</measure>
    <time_frame>Month 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard Care</intervention_name>
    <description>Standard care</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Subjects, age &gt; 18 years

          2. Subjects receiving a single organ renal transplant from a living donor

          3. Positive T-cell and/or B-cell crossmatch by complement dependent cytotoxicity (CDC)
             and/or positive flow cytometry crossmatch with confirmed donor-specific antibodies on
             solid-phase assay at screening. Positive CDC T-cell and/or B-cell crossmatch titre
             must be less than or equal to 1:64.

          4. Subjects capable of understanding the purposes and risks of the study and who can give
             written informed consent

        Exclusion Criteria at Study Entry (4 weeks prior to transplant):

          1. Primary renal transplant lost from acute rejection less than six months prior to
             randomisation

          2. Women of childbearing potential with a positive serum or urine pregnancy test or
             nursing mothers

          3. Subjects with history of malignancy (other than non melanoma skin cancer that has been
             totally excised with no recurrence for two years)

          4. Subjects with known contraindications to treatment with rituximab

          5. Subjects with haemoglobin &lt; 8.5 g/dL, WBC value of &lt; 3000/mm3 or a platelet count of &lt;
             50,000/mm3 that is unlikely to resolve prior to randomisation

          6. Subjects with a positive ABO crossmatch with donor

          7. Subjects with severe diarrhoea or other gastrointestinal disorders that might
             interfere with the ability to absorb oral medication and is unlikely to resolve prior
             to randomisation

          8. Subjects participating in another interventional clinical trial or requiring treatment
             with un-marketed investigational drugs or who would be expected to require other
             medications prohibited by the protocol

          9. Subjects who cannot be followed for the study duration

         10. Subjects with disorders or conditions that may interfere with the ability to comply
             with study procedures and/or requirements

        Additional Exclusion Criteria at Day -2 before Transplantation:

          1. All exclusion criteria as at study entry

          2. Positive T- and/or B-cell CDC crossmatch at Day -2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul R Trevillian, MBBS, FRACP</last_name>
    <role>Study Chair</role>
    <affiliation>Newcastle Transplant Unit, John Hunter Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Solomon Cohney, MBBS, FRACP, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul R Trevillian, MBBS, FRACP</last_name>
    <phone>+61414417311</phone>
    <email>Paul.Trevillian@hnehealth.nsw.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Solomon Cohney, MBBS, FRACP, PhD</last_name>
    <phone>+61393427159</phone>
    <email>Solomon.Cohney@wh.org.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Newcastle Transplant Unit, John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul R Trevillian, MBBS, FRACP</last_name>
      <phone>+61249214326</phone>
      <email>Paul.Trevillian@hnehealth.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Ann Stein, RN</last_name>
      <phone>+61249214341</phone>
      <email>Ann.Stein@hnehealth.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Paul R Trevillian, MBBS, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Kanellis, MBBS, PhD, FRACP</last_name>
      <phone>+61395943070</phone>
      <email>john.kanellis@med.monash.edu.au</email>
    </contact>
    <contact_backup>
      <last_name>Janet Andrew</last_name>
      <phone>+61395943526</phone>
      <email>j.andrew@southernhealth.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>John Kanellis, MBBS, PhD, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shlomo Cohney, MBBS</last_name>
      <phone>+61393427159</phone>
      <email>Solomon.Cohney@wh.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Maria Farrell</last_name>
      <phone>+61393427077</phone>
      <email>maria.farrell@mh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Shlomo Cohney, MBBS, PhD, FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2006</study_first_submitted>
  <study_first_submitted_qc>September 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2006</study_first_posted>
  <last_update_submitted>May 20, 2008</last_update_submitted>
  <last_update_submitted_qc>May 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2008</last_update_posted>
  <keyword>Rituximab</keyword>
  <keyword>donor</keyword>
  <keyword>sensitised</keyword>
  <keyword>antibody</keyword>
  <keyword>rejection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

